Latest Regulatory Progress News

Page 3 of 58
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026
Bounty Oil & Gas reported a larger FY2026 loss and weaker production, while reshaping its portfolio around Queensland oil development and a proposed deepwater Liberia entry. The strategy is backed by fresh equity, but depends on further funding, regulatory progress and a production sharing contract that has not yet been finalised.
Victor Sage
Victor Sage
16 Oct 2026
Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.
Ada Torres
Ada Torres
9 Oct 2026
Daly Resources has emerged from its June ASX debut with $11.05 million in cash, a 6,500 km² Northern Territory exploration portfolio and a growing list of drill targets. The catch is familiar for early-stage explorers: the company has yet to define a mineral resource or reserve, while its strongest Huckitta results remain surface sampling rather than drilling.
Maxwell Dee
Maxwell Dee
8 Oct 2026
ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.
Victor Sage
Victor Sage
5 Oct 2026
Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026
Titanium Sands has warned of material uncertainty over its ability to continue as a going concern, with just $112,578 in cash and $1.8 million of convertible notes due for repayment or conversion. The warning comes as the company prepares to submit the Environmental Impact Assessment for its Mannar Island mineral sands project in October.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.
Ada Torres
Ada Torres
30 Sept 2026
D3 Energy has lifted its combined 2C recoverable helium resource by 65% to 35.6 BCF while securing A$6.12 million in fresh capital. The annual report also shows the cost of advancing the portfolio, with the FY2026 loss widening to A$6.11 million and operating cash outflow reaching A$3.84 million.
Maxwell Dee
Maxwell Dee
24 Sept 2026
KALiNA Power returned to profit in FY2026 after booking A$19.6 million from the sale of a 180 MW Alberta load allocation linked to Meta. The company now has A$12.3 million in cash and four gas-fired power projects targeting about 900 MW, but future progress depends on fresh capital and project approvals.
Victor Sage
Victor Sage
24 Sept 2026
Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.
Ada Torres
Ada Torres
23 Sept 2026
Elementos has materially strengthened its balance sheet while moving its Spanish Oropesa tin project closer to permitting, financing and a final investment decision. The annual report also highlights a doubling of Cleveland’s inferred tungsten resource, but both projects still require substantial capital and further approvals.
Maxwell Dee
Maxwell Dee
21 Sept 2026

Browse the archive

Full archive